drugset / Trial / NCT00005002

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

NCT00005002 ↗

Phase 3 Unknown 688 enrolled Agouron Pharmaceuticals
Double-blindTreatment

Summary

The purpose of this study is to see if it is effective to add an HIV vaccine (Remune) to the anti-HIV drug combination of Combivir (zidovudine plus lamivudine) and nelfinavir.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Remune Vaccine — —
Background Lamivudine Other / unclassified — —
Background Nelfinavir Other / unclassified — —
Background Zidovudine Small molecule — —